Literature DB >> 8701879

Ventricular premature beat-driven intermittent restoration of coronary blood flow reduces the incidence of reperfusion-induced ventricular fibrillation in a cat model of regional ischemia.

H S Na1, Y I Kim, Y W Yoon, H C Han, S H Nahm, S K Hong.   

Abstract

With a cat model of regional cardiac ischemia, we examined whether the incidence of reperfusion-induced ventricular fibrillation (VF) could be reduced by ventricular premature beat (VPB)-driven intermittent reperfusion. In addition, we assessed whether the effect of the intermittent reperfusion was comparable with that of ischemic preconditioning in suppressing the VF. Of 15 cats subjected to uninterrupted reperfusion after 20-minute occlusion of the left anterior descending coronary artery, 13 (86.70%) had VF, whereas only 1 (7.1%) of 14 cats subjected to the VPB-driven intermittent reperfusion had VF. This incidence of VF was significantly lower than that of the animal group subjected to uninterrupted reperfusion. However, it was not statistically different from that (3 of 15) of the group subjected to a 10-minute episode of the coronary artery occlusion before the 20-minute occlusion (i.e., "ischermic preconditioning"). Our results suggest that the VPB-driven intermittent reperfusion (i.e., "postconditioning") is very effective in preventing reperfusion-induced VF and as good as, if not better than, ischemic preconditioning.

Entities:  

Mesh:

Year:  1996        PMID: 8701879     DOI: 10.1016/s0002-8703(96)90393-2

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  26 in total

1.  Induction of ischemic tolerance protects the retina from diabetic retinopathy.

Authors:  Diego C Fernandez; Pablo H Sande; Mónica S Chianelli; Hernán J Aldana Marcos; Ruth E Rosenstein
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

Review 2.  Current Modalities and Mechanisms Underlying Cardioprotection by Ischemic Conditioning.

Authors:  John H Rosenberg; John H Werner; Michael J Moulton; Devendra K Agrawal
Journal:  J Cardiovasc Transl Res       Date:  2018-05-24       Impact factor: 4.132

Review 3.  The Role of NMDA Receptors in the Development of Brain Resistance through Pre- and Postconditioning.

Authors:  Leandra Celso Constantino; Carla Inês Tasca; Carina Rodrigues Boeck
Journal:  Aging Dis       Date:  2014-02-12       Impact factor: 6.745

4.  The Protective Effects of Ischemic Postconditioning against Stroke: From Rapid to Delayed and Remote Postconditioning.

Authors:  Heng Zhao
Journal:  Open Drug Discov J       Date:  2011-12-24

Review 5.  From rapid to delayed and remote postconditioning: the evolving concept of ischemic postconditioning in brain ischemia.

Authors:  Heng Zhao; Chuancheng Ren; Xingmiao Chen; Jiangang Shen
Journal:  Curr Drug Targets       Date:  2012-02       Impact factor: 3.465

Review 6.  Hydrogen sulfide-mediated myocardial pre- and post-conditioning.

Authors:  Benjamin L Predmore; David J Lefer
Journal:  Expert Rev Clin Pharmacol       Date:  2011-01       Impact factor: 5.045

Review 7.  Clinical application of preconditioning and postconditioning to achieve neuroprotection.

Authors:  Cameron Dezfulian; Matthew Garrett; Nestor R Gonzalez
Journal:  Transl Stroke Res       Date:  2012-11-15       Impact factor: 6.829

8.  Ischemic post-conditioning reduces infarct size of the in vivo rat heart: role of PI3-K, mTOR, GSK-3beta, and apoptosis.

Authors:  Claudia Wagner; Diana Tillack; Gregor Simonis; Ruth H Strasser; Christof Weinbrenner
Journal:  Mol Cell Biochem       Date:  2010-01-07       Impact factor: 3.396

9.  Ischemic postconditioning protects against focal cerebral ischemia by inhibiting brain inflammation while attenuating peripheral lymphopenia in mice.

Authors:  S P Joo; W Xie; X Xiong; B Xu; H Zhao
Journal:  Neuroscience       Date:  2013-04-13       Impact factor: 3.590

Review 10.  Protective ischaemia in patients: preconditioning and postconditioning.

Authors:  Asger Granfeldt; David J Lefer; Jakob Vinten-Johansen
Journal:  Cardiovasc Res       Date:  2009-04-27       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.